Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.61 |
| ▸ | NPY4R | P50391 | 12/20 | 0.54 |
| ▸ | NPY1R | P25929 | 7/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL29245680 | 0.97 | SLC7A5 (0.58) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL11100070 | 0.96 | SLC7A5 (0.57) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL28440222 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL27729866 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL21253169 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL9745063 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL29144188 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL28465850 | 0.95 | SLC7A5 (0.56) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL7086081 | 0.94 | SLC7A5 (0.55) | SLC7A5NPY4RNPY1RNPY2RNPY5R | |
| Tyrosine SCHEMBL29276359 | 0.94 | SLC7A5 (0.55) | SLC7A5NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1283657-C | Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities | STAGO DIAGNOSTICA (FR) | 2006-11-08 | — | — | CN | claimed |
| CN-1524087-A | Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities | — | 2004-08-25 | — | — | CN | claimed |
| CN-115969729-A | Clathrate compound of acetyl dipeptide-1 cetyl ester and preparation method thereof | 深圳市迪克曼生物科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-114164198-A | (R) - (-) -3- (carbamoylmethyl) -5-methylhexanoic acid synthetic protein, mutant and application thereof | 中国科学院微生物研究所 | 2022-03-11 | — | — | CN | disclosed |
| EP-3361986-B1 | AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES | UNIV LOS ANDES (CL) | 2021-01-06 | — | — | EP | disclosed |
| US-10688694-B2 | Automated fabrication of layer-by-layer tissue engineered complex tubes | UNIVERSIDAD DE LOS ANDES (CL) | 2020-06-23 | — | — | US | disclosed |
| EP-3638327-A1 | METHOD FOR PRODUCING MULTILAYERED COMPOSITES AND THEIR USES | Cells For Cells S.A. (CL) | 2020-04-22 | — | — | EP | disclosed |
| US-20190083407-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | GRUNENTHAL GMBH (DE) | 2019-03-21 | — | — | US | disclosed |
| WO-2018229734-A1 | METHOD FOR PRODUCING MULTILAYERED COMPOSITES AND THEIR USES | CELLS FOR CELLS, S.A (CL) | 2018-12-20 | — | — | WO | disclosed |
| US-20180304502-A1 | AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES | UNIVERSIDAD DE LOS ANDES (CL) | 2018-10-25 | — | — | US | disclosed |
| US-10093691-B2 | Crystallization method and bioavailability | GRUNENTHAL GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| CN-100536909-C | method for preventing mitochondrial permeability transition | CORNELL RES FOUNDATION INC CLI (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-100506841-C | Method and carrier complex for delivering molecules to cells | CORNELL RES FOUNDATION INC (US) | 2009-07-01 | — | — | CN | disclosed |
| CN-101440124-A | Methods for preventing mitochondrial permeability transition | CORNELL RES FOUNDATION INC (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101214380-A | Method and carrier complexes for delivering molecules to cells | CORNELL RES FOUNDATION INC (US) | 2008-07-09 | — | — | CN | disclosed |
| EP-1833571-A1 | COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES | LABO Cosprophar AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070148118-A1 | Cosmetic composition for skin application suitable for relaxing expression wrinkles | LABO COSPROPHAR AG (CH) | 2007-06-28 | — | — | US | disclosed |
| WO-2006069608-A1 | COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES | LABO COSPROPHAR AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| EP-0804460-A1 | CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO | MOLECUMETICS, LTD. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022304-A1 | CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO | MOLECUMETICS, LTD. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093691-B2 | Crystallization method and bioavailability | ABCG2, GYS2, PYGL | SLC7A5 445/4885NPY4R 1320/4885NPY1R 1027/4885 |
| US-20190083407-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | ABCG2, GYS2, PYGL | SLC7A5 445/4885NPY4R 1320/4885NPY1R 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.